Reply to “High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis” by Messori et al.

Những quyển sách tương tự

• High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis
  Bằng: Messori, Andrea, et al.
  Được phát hành: (2018)
• Further comments on “High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis”
  Bằng: Messori, Andrea, et al.
  Được phát hành: (2019)
• Recombinant factor VIII Fc for the treatment of haemophilia A
  Bằng: Hermans, Cedric, et al.
  Được phát hành: (2021)
• Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better
  Bằng: Franchini, Massimo
  Được phát hành: (2010)
• PROTECT VIII Kids: BAY 94‐9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A
  Bằng: Santagostino, Elena, et al.
  Được phát hành: (2020)